Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479462 | 0.81 | EGFR (0.64) | ADORA3ADORA2AADORA1EGFRTRPV1 | |
| SCHEMBL13675051 | 0.79 | EGFR (0.78) | EGFRTRPV1 | |
| SCHEMBL13675195 | 0.78 | EGFR (0.77) | EGFRTRPV1DYRK1A | |
| SCHEMBL4483368 | 0.76 | EGFR (0.69) | EGFRMEN1KMT2A | |
| SCHEMBL13675052 | 0.74 | EGFR (0.59) | EGFRTRPV1 | |
| SCHEMBL14462120 | 0.71 | EGFR (0.56) | EGFR | |
| SCHEMBL9726894 | 0.69 | ABCG2 (0.54) | EGFRDYRK1ADYRK1BABCG2GSK3B | |
| SCHEMBL1182248 | 0.68 | SYK (0.52) | ADORA3DYRK1AABCG2GSK3BKDM4E | |
| SCHEMBL1881253 | 0.68 | CDC7 (0.61) | ADORA3DYRK1AABCG2GSK3BKDM4E | |
| SCHEMBL1821911 | 0.66 | NPC1 (0.69) | CSNK1DCSNK1G2ABCG2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| EP-1912639-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | ABL1, MAP3K19, PI4KB | ADORA3 2137/4885ADORA2A 1956/4885ADORA1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.